- Open
- 201.40
- High
- 201.80
- Low
- 197.00
- Close
- 199.00
- Change
- -3.00 (-1.49%)
- Volume
- 21,083
| 29 Oct 2026 | 07:00:04 | US FDA Grants Sovleplenib Orphan Drug Designation |
| 27 Oct 2026 | 07:00:04 | HUTCHMED to Host Event on Recent Savolitinib Data |
| 26 Oct 2026 | 08:30:01 | SANOVO Phase III Data at ESMO |
| 26 Oct 2026 | 07:00:10 | SAFFRON Phase III Data ESMO & NEJM Publication |
Hutchmed (China) Limited is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases. The company operates in the commercial stage, with its first three medicines marketed in China and one approved in multiple international markets, including the US, Europe, and Japan. Hutchmed aims to bring drug candidates from in-house discovery to patients globally.
| 29 Oct 2026 | 07:00:04 | US FDA Grants Sovleplenib Orphan Drug Designation |
| 27 Oct 2026 | 07:00:04 | HUTCHMED to Host Event on Recent Savolitinib Data |
| 26 Oct 2026 | 08:30:01 | SANOVO Phase III Data at ESMO |
| 26 Oct 2026 | 07:00:10 | SAFFRON Phase III Data ESMO & NEJM Publication |
Hutchmed (China) Limited is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases. The company operates in the commercial stage, with its first three medicines marketed in China and one approved in multiple international markets, including the US, Europe, and Japan. Hutchmed aims to bring drug candidates from in-house discovery to patients globally.
| 21 Oct 2026 | 07:00:04 | KRAS-EGFR-Antibody licensing deal with GSK closes |
| 21 Oct 2026 |
| HUTCHMED closes GSK cancer therapy licence deal worth up to $1.3 billion |
| 3 Sept 2026 | AIM movers: Hutchmed licence deal with GSK and Futura Medical assessing potential sale |
| 3 Sept 2026 | Hutchmed (China) soars on GSK licence deal |
| 3 Sept 2026 | Panmure and Cavendish reiterate buy on Hutchmed after GSK deal |
| 3 Sept 2026 | HUTCHMED shares jump 17% on US$1.3 billion GSK cancer drug deal |
| 17 Aug 2026 | HUTCHMED shares rise as lung cancer drug trial hits key targets |
| 21 Oct 2026 | 07:00:04 | KRAS-EGFR-Antibody licensing deal with GSK closes |
| 21 Oct 2026 |
| HUTCHMED closes GSK cancer therapy licence deal worth up to $1.3 billion |
| 3 Sept 2026 | AIM movers: Hutchmed licence deal with GSK and Futura Medical assessing potential sale |
| 3 Sept 2026 | Hutchmed (China) soars on GSK licence deal |
| 3 Sept 2026 | Panmure and Cavendish reiterate buy on Hutchmed after GSK deal |
| 3 Sept 2026 | HUTCHMED shares jump 17% on US$1.3 billion GSK cancer drug deal |
| 17 Aug 2026 | HUTCHMED shares rise as lung cancer drug trial hits key targets |
| Issuer | Mkt cap | 1Y |
|---|---|---|
HCMHutchmed (China) Limited | £1.74bn | -0.1% |
| £276m | +0.0% | |
| £107m | -0.1% | |
| £49m | +0.7% | |
| £37m | -0.8% | |
| £26m | +0.0% |
| Issuer | Mkt cap | 1Y |
|---|---|---|
HCMHutchmed (China) Limited | £1.74bn | -0.1% |
| £276m | +0.0% | |
| £107m | -0.1% | |
| £49m | +0.7% | |
| £37m | -0.8% | |
| £26m | +0.0% |